Fig. 4From: Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapyROC curves of relative change in NLR and TLR from baseline at 3-weeks follow-up in predicting objective response at 3 months (top row) and 6 months (bottom row), according to RECIST 1.1. AUC area under the curveBack to article page